Marta Del Pino1,2, Cristina Martí1, Ines Torras1, Carla Henere1, Meritxell Munmany1, Lorena Marimon3, Adela Saco3, Aureli Torné1,2, Jaume Ordi3,4. 1. Institute Clinic of Gynecology, Obstetrics, and Neonatology, Hospital Clínic, 08036 Barcelona, Spain. 2. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036 Barcelona, Spain. 3. Department of Pathology, Hospital Clínic, University of Barcelona, 08036 Barcelona, Spain. 4. Institute for Global Health (ISGlobal), Hospital Clínic, Universitat de Barcelona, 08036 Barcelona, Spain.
Abstract
Background: Recent studies have shown preliminary evidence that vaccination against human papillomavirus (HPV) could decrease the risk of persistent/recurrent HSIL in women treated for high-grade cervical intraepithelial lesion (HSIL). We aimed to determine the benefits of HPV vaccination in patients undergoing conization for HSIL in real-life conditions and evaluate vaccination compliance associated with different funding policies. Methods: From January 2013 to July 2018, 265 women underwent conization in our center. From January 2013 to July 2017, treated patients (n = 131) had to pay for the vaccine, whereas after July 2017 the vaccine was publicly funded and free for treated women (n = 134). Post-conization follow-up controls were scheduled every six months with a Pap smear, HPV testing, and a colposcopy. Results: 153 (57.7%) women accepted vaccination (vaccinated group), and 112 (42.3%) refused the vaccine (non-vaccinated group). Persistent/recurrent HSIL was less frequent in vaccinated than in non-vaccinated women (3.3% vs. 10.7%, p = 0.015). HPV vaccination was associated with a reduced risk of persistent/recurrent HSIL (OR 0.2, 95%CI: 0.1-0.7, p = 0.010). Vaccination compliance increased when the vaccine was publicly funded (from 35.9% [47/131] to 79.1% [106/134], p < 0.001). Conclusions: HPV vaccination in women undergoing conization is associated with a 4.5-fold reduction in the risk of persistent/recurrent HSIL. Vaccination policies have an important impact on vaccination compliance.
Background: Recent studies have shown preliminary evidence that vaccination against human papillomavirus (HPV) could decrease the risk of persistent/recurrent HSIL in women treated for high-grade cervical intraepithelial lesion (HSIL). We aimed to determine the benefits of HPV vaccination in patients undergoing conization for HSIL in real-life conditions and evaluate vaccination compliance associated with different funding policies. Methods: From January 2013 to July 2018, 265 women underwent conization in our center. From January 2013 to July 2017, treated patients (n = 131) had to pay for the vaccine, whereas after July 2017 the vaccine was publicly funded and free for treated women (n = 134). Post-conization follow-up controls were scheduled every six months with a Pap smear, HPV testing, and a colposcopy. Results: 153 (57.7%) women accepted vaccination (vaccinated group), and 112 (42.3%) refused the vaccine (non-vaccinated group). Persistent/recurrent HSIL was less frequent in vaccinated than in non-vaccinated women (3.3% vs. 10.7%, p = 0.015). HPV vaccination was associated with a reduced risk of persistent/recurrent HSIL (OR 0.2, 95%CI: 0.1-0.7, p = 0.010). Vaccination compliance increased when the vaccine was publicly funded (from 35.9% [47/131] to 79.1% [106/134], p < 0.001). Conclusions: HPV vaccination in women undergoing conization is associated with a 4.5-fold reduction in the risk of persistent/recurrent HSIL. Vaccination policies have an important impact on vaccination compliance.
Authors: Luca De Toni; Francesco Muscianisi; Christian Corsini; Marco Ghezzi; Andrea Di Nisio; Carlo Foresta; Andrea Garolla Journal: Vaccines (Basel) Date: 2020-12-07
Authors: Violante Di Donato; Giuseppe Caruso; Marco Petrillo; Evangelos Kontopantelis; Innocenza Palaia; Giorgia Perniola; Francesco Plotti; Roberto Angioli; Ludovico Muzii; Pierluigi Benedetti Panici; Giorgio Bogani Journal: Vaccines (Basel) Date: 2021-04-21
Authors: Violante Di Donato; Giuseppe Caruso; Giorgio Bogani; Eugenio Nelson Cavallari; Gaspare Palaia; Giorgia Perniola; Massimo Ralli; Sara Sorrenti; Umberto Romeo; Angelina Pernazza; Alessandra Pierangeli; Ilaria Clementi; Andrea Mingoli; Andrea Cassoni; Federica Tanzi; Ilaria Cuccu; Nadia Recine; Pasquale Mancino; Marco de Vincentiis; Valentino Valentini; Gabriella d'Ettorre; Carlo Della Rocca; Claudio Maria Mastroianni; Guido Antonelli; Antonella Polimeni; Ludovico Muzii; Innocenza Palaia Journal: Vaccines (Basel) Date: 2022-02-04
Authors: Andrea Casajuana-Pérez; Mar Ramírez-Mena; Estefanía Ruipérez-Pacheco; Inés Gil-Prados; Javier García-Santos; Mónica Bellón-Del Amo; Juan J Hernández-Aguado; Jesus de la Fuente-Valero; Ignacio Zapardiel; Pluvio J Coronado-Martín Journal: Vaccines (Basel) Date: 2022-02-14
Authors: Konstantinos S Kechagias; Ilkka Kalliala; Sarah J Bowden; Antonios Athanasiou; Maria Paraskevaidi; Evangelos Paraskevaidis; Joakim Dillner; Pekka Nieminen; Bjorn Strander; Peter Sasieni; Areti Angeliki Veroniki; Maria Kyrgiou Journal: BMJ Date: 2022-08-03